Other News To Note
Wednesday, April 10, 2013
InDex Pharmaceuticals AB, of Stockholm, Sweden, completed enrollment for its Phase III COLLECT study of Kappaproct.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.